JCN Newswire
TOKYO, May 28, 2025 – (JCN Newswire) – Eisai Co., Ltd. announced today that the in-house-discovered and developed orexin receptor antagonist DAYVIGO® (generic name: lemborexant) has been approved in China for the treatment of adults with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance…
Read More
New Drug Approval for In-House Developed Anti-Insomnia Drug DAYVIGO (Lemborexant) in China
Elroy Damron
14:30
TOKYO, May 28, 2025 – (JCN Newswire) – Eisai Co., Ltd. announced today that the in-house-discovered and developed orexin receptor antagonist DAYVIGO® (generic name: lemborexant) has been approved in China for the treatment of adults with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance…
